Article
Death receptor 6 as prognostic marker in low grade glioma
Death Receptor 6 als prognostischer Marker in LGG
Search Medline for
Authors
Published: | May 25, 2022 |
---|
Outline
Text
Objective: Low grade glioma (LGG) are heterogenous tumours, causing variable survival in patients. Identifying molecular markers for a more accurate prognosis is therefore important. Since death receptor 6 (DR6) is upregulated in glioma and shows an aberrant signalling network, we tested its suitability as prognostic marker.
Methods: DR6 was investigated in patient samples via PCR and Western Blot. Clinical data was analysed and compared to The Cancer Genome Atlas (TCGA) “brain lower grade glioma” dataset.
Results: DR6 is enhanced in LGG and its expression increases in recurrent LGG. DR6 mRNA expression was enhanced in tumour samples (0.2418 ± 0.1762 vs. 0.08442 ± 0.02662, p=0.0031). On the protein level, the receptor was increased in cancer samples, though not significantly (0.2634 ± 0.1187 vs. 0.1688 ± 0.1083). The receptor shows a protective effect in primary LGG with a significantly elongated progression free survival that was confirmed in the TCGA study. This effect is reversed in relapsed LGG in which cases with high DR6 expression reveal a shorter overall survival. We analysed only the primary LGG tumour samples in our study which exhibited a significantly longer PFS for cases with high DR6 expression compared to samples with low DR6 level (HR 0.4094, 95% CI 0.1968 to 0.8516) (Figure 4c). This effect was independent of other prognostic factors.
Conclusion: DR6 is an interesting candidate for further studies regarding its effect as a prognostic marker, playing an opposing role in primary and relapsed LGG.